150 related articles for article (PubMed ID: 1489207)
1. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa.
Jakics EB; Iyobe S; Hirai K; Fukuda H; Hashimoto H
Antimicrob Agents Chemother; 1992 Nov; 36(11):2562-5. PubMed ID: 1489207
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa.
Poole K; Gotoh N; Tsujimoto H; Zhao Q; Wada A; Yamasaki T; Neshat S; Yamagishi J; Li XZ; Nishino T
Mol Microbiol; 1996 Aug; 21(4):713-24. PubMed ID: 8878035
[TBL] [Abstract][Full Text] [Related]
3. Cloning and characterization of a DNA fragment that complements the nfxB mutation in Pseudomonas aeruginosa PAO.
Okazaki T; Iyobe S; Hashimoto H; Hirai K
FEMS Microbiol Lett; 1991 Mar; 63(1):31-5. PubMed ID: 1904383
[TBL] [Abstract][Full Text] [Related]
4. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa.
Hirai K; Suzue S; Irikura T; Iyobe S; Mitsuhashi S
Antimicrob Agents Chemother; 1987 Apr; 31(4):582-6. PubMed ID: 3111356
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.
Yoshida T; Muratani T; Iyobe S; Mitsuhashi S
Antimicrob Agents Chemother; 1994 Jul; 38(7):1466-9. PubMed ID: 7979273
[TBL] [Abstract][Full Text] [Related]
6. Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ.
Hosaka M; Gotoh N; Nishino T
Antimicrob Agents Chemother; 1995 Aug; 39(8):1731-5. PubMed ID: 7486910
[TBL] [Abstract][Full Text] [Related]
7. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO.
Fukuda H; Hosaka M; Hirai K; Iyobe S
Antimicrob Agents Chemother; 1990 Sep; 34(9):1757-61. PubMed ID: 2126688
[TBL] [Abstract][Full Text] [Related]
8. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin.
Li XZ; Livermore DM; Nikaido H
Antimicrob Agents Chemother; 1994 Aug; 38(8):1732-41. PubMed ID: 7986003
[TBL] [Abstract][Full Text] [Related]
9. [Development of multi-drug resistant mutants of clinical isolates of Pseudomonas aeruginosa after exposure to fluoroquinolone].
Hasegawa M; Kobayashi I; Saika T; Shimadzu M; Nishida M
Kansenshogaku Zasshi; 1996 Feb; 70(2):123-31. PubMed ID: 8851384
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Livermore DM; Yang YJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
[TBL] [Abstract][Full Text] [Related]
11. [Antimicrobial activities of norfloxacin against clinical isolates from ocular infections].
Koguchi M; Suzuki Y; Tanaka S; Fukayama S; Ishihara R; Deguchi K; Oda S; Nakane Y; Fukumoto T
Jpn J Antibiot; 1995 Aug; 48(8):1009-25. PubMed ID: 7474324
[TBL] [Abstract][Full Text] [Related]
12. In vitro sensitivity of isolates of Pseudomonas aeruginosa to carbenicillin, gentamicin, tobramycin, and some other antibiotics.
Wretland B; Nord CE; Wadström T
Scand J Infect Dis; 1974; 6(1):49-52. PubMed ID: 4208204
[No Abstract] [Full Text] [Related]
13. Transferable imipenem resistance in Pseudomonas aeruginosa.
Watanabe M; Iyobe S; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1991 Jan; 35(1):147-51. PubMed ID: 1901695
[TBL] [Abstract][Full Text] [Related]
14. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
Aubert G; Pozzetto B; Dorche G
J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
[TBL] [Abstract][Full Text] [Related]
15. Studies on the susceptibility of 150 consecutive clinical isolates of Pseudomonas aeruginosa to tobramycin, gentamicin, colistin, carbenicillin, and five other antimicrobials.
Lockwood WR; Lawson LA
Antimicrob Agents Chemother; 1973 Sep; 4(3):281-4. PubMed ID: 4202342
[TBL] [Abstract][Full Text] [Related]
16. Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques.
Young ML; Bains M; Bell A; Hancock RE
Antimicrob Agents Chemother; 1992 Nov; 36(11):2566-8. PubMed ID: 1336952
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of ciprofloxacin and other beta-lactam antibiotics against gentamicin- and carbenicillin-resistant isolates of Pseudomonas aeruginosa.
Sofianou DC; Douboyas JP
J Chemother; 1991 Feb; 3(1):3-5. PubMed ID: 1902252
[TBL] [Abstract][Full Text] [Related]
18. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.
Ogle JW; Reller LB; Vasil ML
J Infect Dis; 1988 Apr; 157(4):743-8. PubMed ID: 3126247
[TBL] [Abstract][Full Text] [Related]
19. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa.
Masuda N; Gotoh N; Ohya S; Nishino T
Antimicrob Agents Chemother; 1996 Apr; 40(4):909-13. PubMed ID: 8849250
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
Chen HY; Livermore DM
J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
